Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020067333 - PHARMACEUTICAL COMPOSITION FOR TREATING FIBROSIS

Publication Number WO/2020/067333
Publication Date 02.04.2020
International Application No. PCT/JP2019/037947
International Filing Date 26.09.2019
IPC
A61K 31/4453 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4453only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/122 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/397 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
397having four-membered rings, e.g. azetidine
A61K 31/40 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
CPC
A61K 31/122
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/397
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
397having four-membered rings, e.g. azetidine
A61K 31/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4453
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4453only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • 株式会社LTTバイオファーマ LTT BIO-PHARMA CO., LTD. [JP]/[JP]
  • 学校法人武蔵野大学 MUSASHINO UNIVERSITY [JP]/[JP]
Inventors
  • 水島 徹 MIZUSHIMA, Tohru
  • 田中 健一郎 TANAKA, Ken-ichiro
Agents
  • 特許業務法人アルガ特許事務所 THE PATENT CORPORATE BODY ARUGA PATENT OFFICE
Priority Data
2018-18281727.09.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION FOR TREATING FIBROSIS
(FR) COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE LA FIBROSE
(JA) 線維症治療用医薬組成物
Abstract
(EN)
To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts without injuring alveolar epithelial cells and thus inhibits lung fibrosis. A pharmaceutical composition for treating fibrosis that comprises a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate of the same. [In formula (I): R1 represents an optionally halogenated C1-4 alkyl group; and l represents an integer of 3-6. In formula (II): n represents an integer of 8-12.]
(FR)
L'invention concerne un nouvel agent thérapeutique pour la fibrose qui induit la mort cellulaire sélective de fibroblastes pulmonaires sans léser les cellules épithéliales alvéolaires et inhibe ainsi la fibrose pulmonaire. L'invention concerne une composition pharmaceutique pour traiter la fibrose qui comprend un composé représenté par la formule (I) ou (II), un sel pharmaceutiquement acceptable de celui-ci ou un solvat de celui-ci. [Dans la formule (I) : R1 représente un groupe alkyle en C1-4 facultativement halogéné; et l représente un nombre entier de 3 à 6. Dans la formule (II) : n représente un nombre entier de 8 à 12.]
(JA)
肺胞上皮細胞に傷害性を示すことなく、肺線維芽細胞の選択的細胞死を誘導し、肺の線維化を抑制する新たな線維症治療薬の提供。 式(I)若しくは式(II)で表される化合物、その医薬として許容し得る塩又はそれらの溶媒和物を含有する、線維症治療用医薬組成物。(式(I)中、R1はハロゲン原子が置換していてもよいC1-4アルキル基を示し、lは3~6の整数を示す。 式(II)中、nは8~12の整数を示す。)
Also published as
Latest bibliographic data on file with the International Bureau